Latest news for  (OTC:SGSSF) Stock

Morgan Stanley analyst Bob Huang initiates coverage on Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) with a Equal-Weight rating and announces Price Target of $251.

News

Price Target

Initiation

Analyst Ratings

Morgan Stanley Initiates Coverage On Assurant with Equal-Weight Rating, Announces Price Target of $251

Morgan Stanley analyst Bob Huang downgrades Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) from Equal-Weight to Underweight and lowers the price target from $86 to $80.

Downgrades

Morgan Stanley Downgrades Principal Finl Gr to Underweight, Lowers Price Target to $80

Stephens &amp; Co. analyst Scott Fidel maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and raises the price target from $605 to $675.

Stephens & Co. Maintains Overweight on UnitedHealth Group, Raises Price Target to $675

<ul>
<li>74.5% of patients achieved a complete response at any time.</li>
<li>Median duration of response is greater than 27 months and not reached.</li>
<li>Latest data update continued to show favorable safety and tolerability results</li>
</ul>

Biotech

Health Care

General

CGON

CG Oncology Announced Topline Data From The Phase 3 BOND-003 Trial In Patients With High-risk Non-muscle Invasive Bladder Cancer Unresponsive To Bacillus Calmette Guerin Demonstrating 74.5% Of Patients Achieved A Complete Response, After Receiving Treatment With Cretostimogene As A Single Agent

Morgan Stanley analyst Meta Marshall upgrades Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from Equal-Weight to Overweight and raises the price target from $23 to $28.

Upgrades

Morgan Stanley Upgrades Hewlett Packard to Overweight, Raises Price Target to $28

Rosenblatt analyst Kevin Cassidy maintains TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy and maintains $10 price target.

WULF

Rosenblatt Maintains Buy on TeraWulf, Maintains $10 Price Target

Morgan Stanley analyst Joseph Moore downgrades Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from Equal-Weight to Underweight and lowers the price target from $179 to $164.

AMAT

Morgan Stanley Downgrades Applied Mat to Underweight, Lowers Price Target to $164

Management

SEDG

SolarEdge Technologies Has Appointed Shuki Nir As The Company's New CEO, Effective Immediately. Mr. Nir, Who Has Served As SolarEdge's CMO Since June 2024, Will Succeed Ronen Faier, Who Has Served As The Company's Interim CEO Since August 2024

Fourth Quarter and Full Year Fiscal 2025 Guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fourth Quarter</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total sales</td>
<td colspan="1" rowspan="1">$2.38 billion to $2.46 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same store sales</td>
<td colspan="1" rowspan="1">Flat to 3%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating income (1)</td>
<td colspan="1" rowspan="1">$397 million to $427 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$441 million to $471 million</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

Signet Jewelers Q4 Outlook: Expects Sales Of $2.38B-$2.46B; And Adj. Operating Income Of $397M-$427M

Rosenblatt analyst Mike Genovese maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Neutral and raises the price target from $60 to $75.

CIEN

Rosenblatt Maintains Neutral on Ciena, Raises Price Target to $75

<ul>
<li>The Company has concurrently executed an agreement to repurchase at least $600 million in aggregate purchase price of shares of its outstanding common stock (from affiliates of Rubric Capital Management LP (collectively, "Rubric"). The Repurchase is priced at a 4% discount to a 15-day VWAP prior to the closing of the Repurchase and is conditioned on the completion of the Financing. This transaction is incremental to the Company's previously announced share repurchase program. That program will have approximately $1.2 billion of remaining capacity available through 2026 after the Company closes the Repurchase.</li>
<li>The proceeds from the Financing will be used, together with cash on hand, to fund the Repurchase, and both transactions are expected to close before December 31, 2024. Subject to market demand, the Company may increase the size of the Financing and use the additional proceeds to purchase additional shares of common stock from Rubric on the same terms as the initial sizing, or for general corporate purposes.</li>
</ul>

Commodities

Markets

Talen Energy Has Launched An Incremental Term Loan B Credit Facility That Will Increase The Principal Term Loan B Balance Under Its Credit Facilities From $859M To Approximately $1.459B, The Company Also Expects To Replace Its Existing Term Loan C Facility With A New Letter Of Credit Facility.

Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) yesterday announced a new partnership with Scality, a global leader in cyber-resilient storage software for the AI era. This strategic collaboration aims to expand Scality's reach across North America, enabling organizations to access scalable, secure, and high-performance storage solutions for their growing data needs.
Under this agreement, Climb Channel Solutions will distribute Scality's portfolio of enterprise-grade storage and backup solutions, including Scality's ARTESCA and RING solutions, to address organizational needs for IT solutions that ensure efficient AI data pipelines and cyber-resilient data protection.

CLMB

Scality Taps Climb Channel Solutions To Distribute Scality's Portfolio Of Enterprise-Grade Storage And Backup Solutions To Address Organizational IT Solutions Needs

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and raises the price target from $635 to $660.

SNPS

Rosenblatt Maintains Buy on Synopsys, Raises Price Target to $660

"Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients"
Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025

GLUE

Monte Rosa Therapeutics Highlights Data From Ongoing MRT-2359 Phase 1/2 Study In Patients With MYC-Driven Solid Tumors

Needham analyst Charles Shi reiterates Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $640 price target.

Reiteration

Needham Reiterates Buy on Synopsys, Maintains $640 Price Target

Interpublic Group Acquires Intelligence Node; Terms Not Disclosed

Fiscal 2025 Guidance
Patterson Companies today revised its fiscal 2025 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted1 basis:
<ul>
<li>GAAP earnings are expected to be in the range of $1.83 to $1.93 per diluted share.</li>
<li>Non-GAAP adjusted earnings1 are expected to be in the range of $2.25 to $2.35 per diluted share.</li>
<li>Our non-GAAP adjusted earnings1 guidance excludes the after-tax impact of:&nbsp; - Deal amortization expenses of approximately $29.9 million ($0.34 per diluted share).&nbsp; - Integration and business restructuring expenses of $7.6 million ($0.09 per diluted share).&nbsp; - Inventory pre-payment write-off of $2.8 million ($0.03 per diluted share).&nbsp; - Investment gain of $2.9 million ($0.03 per diluted share).</li>
</ul>
Our guidance reflects the strength of our business and competitive positioning as well as completed and previously announced acquisitions. It does not include the impact of unplanned share repurchases, potential future acquisitions or similar transactions, impairments, restructuring and integration expenses not previously publicly disclosed, or amortization expense of acquired intangible assets. Our guidance assumes North American and international end market conditions consistent with current market conditions.

PDCO

Patterson Companies Expects 2025 Adjusted EPS Of $2.25-$2.35 Vs. Consensus Of $2.32 And Prior Guidance Of $2.33-$2.43

The new CTO-H provides the largest, longest and deepest view of hematological diseases ever created — establishing a new standard for clinical research

ConcertAI, NeoGenomics Announce AI Software-As-A-Service Solution For Hematology Clinical Research

Rosenblatt analyst Catharine Trebnick maintains Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Buy and maintains $10.5 price target.

Rosenblatt Maintains Buy on Sprinklr, Maintains $10.5 Price Target

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total sales</td>
<td colspan="1" rowspan="1">$6.74 billion to $6.81 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Same store sales</td>
<td colspan="1" rowspan="1">(3%) to (2%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating income (1)</td>
<td colspan="1" rowspan="1">$540 million to $570 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$715 million to $745 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS (1)</td>
<td colspan="1" rowspan="1">$9.62 to $10.08</td>
</tr>
</tbody>
</table>
</figure>

Signet Jewelers Updates FY25 Outlook: Now Expects Adj EPS Of 	$9.62-$10.08 (Prior $9.90-$11.52) vs $10.59 Est., And Sales Of $6.74B-6.81B (Prior $6.66B-$7.02B) vs $6.815B Est.

SPDR Bloomberg SASB U.S. High Yield Corporate ESG UCITS ETF (Dist)

Comments

News

Latest news for (OTC:SGSSF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga